Source: Super Vision；Editor: Bai XiaofeiReprint Requirements: Can be reprinted 24 hours after the first publication, source must be credited.
Recently,Super VisionCarryInnovative Solutions for Ophthalmic Medical TechnologyHeavyweight Appearance at the 49th Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) in 2024. As an international exchange event in the field of ophthalmology, this year's AAPOS has brought together ophthalmology experts, scholars, and corporate representatives from around the world to explore the latest advancements and innovative achievements in ophthalmic healthcare.Super VisionThe"Implantable Ocular Muscle Neurostimulator i-NYS"Gains Wide Attention from International Experts at the Exhibition, attracting a large number of visitors to stop and inquire.Becoming a Major Highlight of the Exhibition。Top ophthalmology experts from multiple countries, including the United States, the United Kingdom, and Australia, gathered at the Super Vision booth.Highly Evaluates the R&D Process and Clinical Progress of i-NYS. Experts believe that,Implantable Electrical Stimulation Therapy Offers a New Approach for the Treatment of Congenital Nystagmus, looking forward to the early launch of i-NYS, benefiting patients with congenital nystagmus worldwide.
▲Source: Official WeChat Account of the Company
"Implantable Ocular Muscle Neurostimulator i-NYS" is a groundbreaking solution for the ophthalmic challenge "Congenital Nystagmus," integratingMedicine, Biomaterials, and Integrated CircuitsInnovative achievements in multiple disciplines.At the exhibition, Super Vision comprehensively sharedMechanism of Action, Development Background, Clinical Trial Progress, and Implantation Process of i-NYS, etc., andMet with the American Nystagmus Network to discuss future educational initiatives and academic exchanges for nystagmus patients. Both parties had in-depth communication and exploration, looking forward to further cooperation in the future.Super Vision Technology, Inc. "Goes Overseas" to the AAPOS Ophthalmology Annual Meeting,Not only showcased the company's innovative achievements, but also demonstrated the innovative strength of China's medical technology.. At the same time, through in-depth exchanges with numerous international ophthalmology experts on the most cutting-edge knowledge and technology in ophthalmology, it also providesSuper Vision Provides a Cutting-Edge Perspective for Further Expansion and Innovation in the Ophthalmology Field。
▲Image source: Company official websitei-NYS is an innovative product with independent intellectual property rights, developed over 19 years by Professor Wang Lejin's team from Peking University People's Hospital.The World's FirstDedicated toTreatment of Congenital NystagmusNew Technology。Super Vision Technology, Inc. (Beijing), founded by Professor Wang Lejin, thisClinical Medical Technology for Product Transformation, developed throughNeuromodulation TechnologyControl of Congenital Nystagmusi-NYS Implantable Ocular Muscle Neurostimulator, isThe World's First and OnlyUsed forTreatment of Congenital NystagmusThe third class of active implantable medical devices is expected to completely solve the treatment challenges of nystagmus.i-NYS Implant and Its Unique Electrode, ThroughMicrocurrent Stimulation of Ocular Muscles, thereby inhibiting the abnormal nerve impulses of congenital nystagmus, achieving the purpose of suppressing nystagmus.。i-NYS has obtained multiple patents domestically and internationally, and has beenIn 2023, at Beijing Chaoyang Hospital, Beijing Tongren Hospital, and Beijing Children's HospitalSuccessfully completed clinical implantation in 71 patients, including the implantation in 45 adult and 26 pediatric patients,Good efficacy achieved in the treatment of nystagmus。February 2024,i-NYS Through the special review application for Class III innovative medical devices by the National Medical Products Administration (NMPA), entering the "green channel" of the special review process.。Wang Wensi, Chief Scientist of Super Vision and Professor at the Faculty of Information Technology, Beijing University of Technology, explained:"This implantable eye muscle neurostimulator is a product similar to cochlear implants and pacemakers. It has highly advanced encapsulation, containing..."Wireless Power Supply, throughWireless Energy Transmission, there is a setChip System, used forPerform controlled nerve stimulation in vivo, throughPositive and Negative Reversed, Repetitive and High-Frequency Neural Stimulation", thereby suppressing some of the original abnormal nerve impulses, such as nystagmus, and other issues related to the ocular muscle nervous system."Proven by 8 clinical trials,i-NYSCan reduce tremor frequency and amplitude by more than 50%，Increase Fixation Time by 3 Times，Improve vision from below 0.3 to above 0.5, this isWorld's First True Control of Nystagmus Symptoms, which is also a major breakthrough in medicine.▲Image source: Company's official website
Congenital Nystagmus(Congenital Nystagmus, CN) is called"Incurable Diseases" in the Field of Ophthalmology，It is caused by abnormal neural discharges in the brain, leading to eye oscillation or twitching. It is often induced by genetic mutations, with onset occurring 3-6 months after birth and persisting throughout life.. The incidence rate of nystagmus in the newborn population is one in a thousand.85% of Patients Suffer from Amblyopia, Impacting Quality of Life, severe cases cannot study or work normally, and their lives are severely restricted,Brings a huge burden to families and society.Currently, there are approximately 1.3 million patients with nystagmus in China.Approximately 20,000 new patients are added each year.; There are approximately 7 million patients worldwide,100,000 new cases each year. Current treatment methodsStill mainly rely on surgical treatment, with non-surgical treatment as an auxiliary method, focusing on reducing nystagmus and correcting head position, but these methods are merelyAlleviate symptoms but cannot cure fundamentally.。Ocular Muscle NeurostimulatorThis method can control nystagmus by stimulating the patient, compared with traditional surgical treatment.The effect is more stable, and the long-term prognosis is good.。In 2004, Professor Wang Lejin proposed based on the experimental results of Liberson Functional Electrical Stimulation (FES) technology.Combining Functional Electrical Stimulation (FES) Technology with Extraocular Muscles, creating products that can eliminate nystagmus and improve vision.
Since then, the project has been persisting in experimentation. Around 2008, expert consultation began, and in 2012, the project started to develop equipment. In 2014, the project received the National Major Instrument Project from the National Natural Science Foundation of China. In 2015, it gained RMB 7.1 million in support from the National Natural Science Foundation's Major Instrument Project.In the same year, the project conducted microelectrode stimulation experiments on the eye muscles of clinical patients, and the results showed that,Microcurrent and abnormal neural discharge mutually superimpose and neutralize, inhibiting abnormal nerve impulses with significant effect.。Professor Wang Lejin introduced that this intelligent nystagmus neuromuscular electrical stimulator product is expected to fill the gap in the treatment of nystagmus.The market space in China is expected to reach 20-40 billion yuan., andThe global market size will exceed 10 billion.。# Meeting of International NetizensDuring the AAPOS conference, Super Vision's booth welcomed a special guest, Josh from Canada, a friend with congenital nystagmus.Josh learned about the innovative product i-NYS for treating congenital nystagmus on the Internet,And communicated with the company multiple times via email, hoping to understand whether this technology is suitable for his situation.. Ultimately, this transnational "online friend" meeting, spanning over ten thousand kilometers, was realized at the AAPOS conference.
▲A 14,000-Kilometer Journey: A U.S. Meet-Up with a Canadian "Internet Friend"
# Super Vision
Super Vision Technology, Inc. (referred to as "Super Vision") was established in 2018 and is a company focused onInnovative Diagnostic and Treatment Technologies in OphthalmologyThe start-up company, jointly founded by ophthalmology experts from Peking University People's Hospital and professors from Beijing University of Technology.
Super VisionDeveloped a rich pipeline of products in research and pre-research, including implantable ocular muscle neurostimulators, myopia treatment devices, implantable glaucoma micro-drainage devices, implantable adjustable intraocular lenses, and strabismus diagnosis and treatment integrated machines. Among them,Implantable Ocular Muscle Neurostimulator isThe world's first and currently onlyProducts That Can Cure Congenital Nystagmus。
Super Vision Technology, Inc.Congenital Nystagmus (CN) Neuromodulation System and TherapyIt is a completely new treatment method for nystagmus, bringing revolutionary changes to the treatment of congenital nystagmus (CN);Corneal/Scleral Cross-Linking TechnologyExplored the possibilities in corneal refractive correction and scleral reinforcement surgery. In addition, the strabismus diagnosis and surgical planning system improves the accuracy of strabismus diagnosis while optimizing the design of strabismus surgery.
Since Super Vision Technology, Inc. settled in the Zhongguan Village Dongsheng International Science Park in 2020, the company has developed rapidly.Currently, it has raised over 100 million yuan in total.In 2020, the prototype of Super Vision's implantable ocular muscle neurostimulator was launched, representing that Chinese companies have mastered the key core technologies in the field of Class III active implantable medical devices, breaking the international technology monopoly; In 2021, a GMP facility was established, allowing the company to independently register products and manufacture. In 2022, Super Vision initiated type inspection; In early 2023, pre-clinical screening and surgical preparation began, with the world's first subject implant surgery successfully completed by Professor Tao Yong from Beijing Chaoyang Hospital.
As of the date of publication, the company has received a total of 5 rounds of financing.The latest round was a nearly 100-million-yuan Series A+ financing in December 2022, led by Fosun Health Capital's Xing Weilai Venture Capital Fund, with participation from Ming Heng Industry Investment and Zhongzhi Zhonghe. The funds will be used for clinical trials of the world’s first eye tremor electrical modulation product and the research and development of a new generation of implantable medical chips, while also accelerating the advancement of new product development for myopia correction.
The company's financing history is as follows:
